Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Diamondback Energy Inc (FANG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Diamondback Energy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Diamondback Energy Inc trades at $186.1 (market cap $51.59B). The key difference: Diamondback Energy Inc is the larger of the two by market cap, and Diamondback Energy Inc pays a 2.4% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FANG | |
|---|---|---|
Market Cap | $39.89B | $51.59B |
Sector | Health | Energy |
52-Week High | $491.22 | $213.69 |
52-Week Low | $278.09 | $134.53 |
Enterprise Value | $38.15B | $65.31B |
Dividend Yield | — | 2.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Diamondback Energy (FANG) trades at $183.39, up 0.76% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed Q1 2026 earnings, beating estimates with EPS of $4.23 versus $3.74 expected, but missed Q4 2025. Revenue grew to $14.93B in 2025, though net income margin compressed to 1.88%. Analyst consensus remains strongly bullish with a $234.50 price target, while recent news highlights sector volatility amid oil price fluctuations and upcoming Q2 2026 earnings on August 3, 2026.
FANG presents a growth opportunity with strong analyst support and expanding revenue, but faces risks from declining profit margins, high P/E of 187.13, and oil market sensitivity. The stock's 22% upside to consensus target is tempered by execution risks and macroeconomic headwinds, requiring careful monitoring of Q2 earnings and oil price trends for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →
